CellSource Co

CellSource Co Rule of 40

The Rule of 40 of CellSource Co (4880.T) as of Nov 20, 2026 is -10.29 %. In the previous year, Rule of 40 was -0.45 % — a change of 2,182.35% (lower).

Rule of 40

-10.29 %

YoY

2,182.35%

Last updated:

Rule of 40 of CellSource Co is 2025 -10.29 % . Rule of 40 of CellSource Co was 2024 -0.45 % . It decreases by 2,182.35% lower compared to the previous year.

The CellSource Co Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2018
157.97 JPY
Jan 1, 2019
53.18 JPY
Jan 1, 2020
37.53 JPY
Jan 1, 2021
91.48 JPY
Jan 1, 2022
83.01 JPY
Jan 1, 2023
33.53 JPY
Jan 1, 2024
-0.45 JPY
Jan 1, 2025
-10.29 JPY
The CellSource Co Rule of 40 history
YEARRule of 40YoY
-10.29 %+2,182.35%
-0.45 %-101.34%
33.53 %-59.61%
83.01 %-9.26%
91.48 %+143.76%
37.53 %-29.42%
53.18 %-66.34%
157.97 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSource Co stock

Rule of 40 of CellSource Co is -10.29 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 CellSource Co since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — CellSource Co

All Key Metrics — CellSource Co